Instrument Inactif

Communiqués Albireo Pharma, Inc. Deutsche Boerse AG

Actions

BDQM

US01345P1066

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

ALBIREO PHARMA, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	02/03/23	AQ
Albireo Pharma, Inc. - FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay in Alagille Syndrome	15/02/23	AQ
ALBIREO PHARMA, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	14/02/23	AQ
FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay® in Alagille Syndrome	14/02/23	AQ
ALBIREO PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Albireo Pharma, Inc. - ALBO	24/01/23	BU
ALBIREO PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Albireo Pharma, Inc. - ALBO	11/01/23	BU
ALERT: The M&A Class Action Firm Announces the Investigation of Albireo Pharma, Inc. - ALBO	10/01/23	PR
Shareholder Alert: Ademi LLP investigates whether Albireo Pharma, Inc. has obtained a Fair Price in its transaction with Ipsen	09/01/23	PR
ALBO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Albireo Pharma, Inc. Is Fair to Shareholders	09/01/23	BU
Albireo Pharma : Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases - Form 8-K	09/01/23	PU
ALBIREO PHARMA, INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	09/01/23	AQ
Albireo Pharma : Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases	09/01/23	PU
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	20/12/22	AQ
Albireo Submits Bylvay® Alagille Syndrome Regulatory Filings to FDA and EMA	19/12/22	AQ
Albireo Appoints Paul Streck, M.D., as Chief Medical Officer and Craig Hopkinson, M.D., to Board of Directors	07/12/22	AQ
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	06/12/22	AQ
ALBIREO PHARMA, INC. : Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	06/12/22	AQ
Albireo Appoints Paul Streck, M.D., as Chief Medical Officer & Craig Hopkinson, M.D., to Board of Directors	06/12/22	AQ
Inscription sur la liste des médicaments remboursables aux assurés sociaux de Bylvay® (odevixibat) pour les patients atteints de PFIC 1 & 2 (à l’exception du sous- type BSEP3 de la PFIC 2) chez les patients âgés de 6 mois et plus	30/11/22	GL
Inscription sur la liste des médicaments remboursables aux assurés sociaux de Bylvay® (odevixibat) pour les patients atteints de PFIC 1 & 2 (à l’exception du sous- type BSEP3 de la PFIC 2) chez les patients âgés de 6 mois et plus	30/11/22	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Albireo Pharma, Inc. Deutsche Boerse AG

Actions

BDQM

US01345P1066

Communiqués

Filtres